Advertisement
05/11/2022

FDA grants Glenmark tentative nod for generic Enstilar

Enstilar foam had a market value of roughly $115.2 million for the 12-month period ending March 2022, according to IQVIA.
Sandra Levy
Senior Editor
Sandra Levy profile picture

The Food and Drug Administration has given Glenmark tentative approval for calcipotriene and betamethasone dipropionate foam 0.005%|0.064%.

The medication is the generic of Leo Pharma’s Enstilar foam.

It is used on the skin (topical) to treat plaque psoriasis in people 12 years of age and older.

Enstilar foam 0.005%|0.064% has a market value of approximately $115.2 million for the 12-month period ending March 2022, according to IQVIA.

    Advertisement
    Advertisement